Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.45 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LTA4H | P09960 | 2/20 | 0.44 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13187503 | 0.94 | HRH3 (0.56) | HRH3HIF1AEPAS1SMN1; SMN2NPC1 | |
| SCHEMBL4591964 | 0.84 | HRH3 (0.59) | HRH3SMN1; SMN2 | |
| SCHEMBL18291425 | 0.82 | HRH3 (0.53) | HRH3HIF1AEPAS1SMN1; SMN2LTA4H | |
| SCHEMBL18291378 | 0.82 | HRH3 (0.53) | HRH3HIF1AEPAS1SMN1; SMN2LTA4H | |
| SCHEMBL20249173 | 0.79 | HRH3 (0.49) | HRH3HIF1AEPAS1SMN1; SMN2LTA4H | |
| SCHEMBL20037986 | 0.79 | HRH3 (0.47) | HRH3SMN1; SMN2LTA4HPDE1B | |
| SCHEMBL20038097 | 0.77 | HRH3 (0.46) | HRH3LTA4H | |
| SCHEMBL20038107 | 0.77 | CXCR4 (0.62) | HRH3 | |
| SCHEMBL1820767 | 0.76 | HRH3 (0.58) | HRH3HIF1AEPAS1SMN1; SMN2NPC1 | |
| SCHEMBL20038572 | 0.75 | HRH3 (0.47) | HRH3NPC1TP53TSHRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| EP-3305785-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2018-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | HRH3 2304/4885HIF1A 3422/4885EPAS1 3583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.